BRAF and neoplasm: Of note, it appears that upfront triple therapy (CDK4/6-BRAF-MEK-inhibitors) may have superior efficacy compared to the addition of CDK4/6 inhibitor after tumor acquisitions of BRAF/MEK inhibitors resistance [87].